Today Sarepta Therapeutics announced preliminary data on the first three LGMD2E patients dosed in the MYO-101 Gene Therapy Trial. Muscle biopsies show that about 50% of muscle fibers show expression of beta-sarcoglycan, the protein which is missing or faulty in